Advertisement

Prevalence and Natural History of Non-metastatic Castrate Resistant Prostate Cancer: A Population-Based Analysis

Published:October 12, 2022DOI:https://doi.org/10.1016/j.clgc.2022.10.003

      Abstract

      Purpose

      To determine the prevalence and natural history of nmCRPC prior to the adoption of novel androgen receptor axis-targeting therapies(ARAT).

      Materials and Methods

      This was a retrospective population-based cohort study of men with nmCRPC in Ontario, Canada between January 2007-March 2018. Patients with prostate cancer, castrate level of testosterone(<1.7nmol/L) and a PSA>2.0ng/mL with a subsequent rise>25% from the nadir, and without metastasis were included. Annual prevalence of nmCRPC was calculated. Crude time from nmCRPC to metastasis and all-cause death are presented as medians with interquartile range(IQR). Predictors of time from nmCRPC to death were compared using univariable and multivariable cox proportional hazard models.

      Results

      We identified 2045 patients with nmCRPC. Median age was 79(IQR:72-84). 984 patients(48.1%) received upfront hormonal therapy while 583(28.5%) received initial radiotherapy and 478(23.4%) underwent radical prostatectomy. Median time from primary treatment to nmCRPC was 6 years(IQR:3-10). The average annual prevalence of nmCRPC was 8% among men receiving ADT. Crude median time from nmCRPC to death was 37.6 months(IQR:22.1-55.4). Median time from nmCRPC to metastasis and metastasis to death was 20.0 and 8.3 months, respectively. Patients who had primary surgery experienced longer crude survival. Older patients, patients who had a higher PSA at nmCRPC, and patients with grade group 4 to 5 disease had a shorter time from nmCRPC to death.

      Conclusion

      This is the largest population-level analysis of the prevalence and natural history of nmCRPC. The current study can be used as a historical cohort to compare how novel imaging modalities and ARAT impact prevalence and disease trajectory over time.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. ACS. American Cancer Society: Key Statistics for Prostate Cancer. Accessed January, 2020. https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html.

        • Dall'Era MA
        • deVere-White R
        • Rodriguez D
        • Cress R.
        Changing incidence of metastatic prostate cancer by race and age, 1988-2015.
        Eur Urol Focus. 2019; 5: 1014
        • Scher HI
        • Morris MJ
        • Stadler WM
        • et al.
        Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3.
        J Clin Oncol. 2016; 34: 1402
        • Smith MR
        • Saad F
        • Chowdhury S
        • et al.
        Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
        N Engl J Med. 2018; 378: 1408
        • Hussain M
        • Fizazi K
        • Saad F
        • et al.
        Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer.
        N Engl J Med. 2018; 378: 2465
        • Fizazi K
        • Shore N
        • Tammela TL
        • et al.
        Darolutamide in nonmetastatic, castration-resistant prostate cancer.
        N Engl J Med. 2019; 380: 1235
        • Bhindi B
        • Karnes RJ.
        Novel nonsteroidal antiandrogens and overall survival in nonmetastatic castration-resistant prostate cancer.
        Eur Urol. 2018; 74: 534
        • Ryan CJ
        • Crawford ED
        • Shore ND
        • et al.
        The IMAAGEN study: effect of abiraterone acetate and prednisone on prostate specific antigen and radiographic disease progression in patients with nonmetastatic castration resistant prostate cancer.
        J Urol. 2018; 200: 344
        • von Elm E
        • Altman DG
        • Egger M
        • et al.
        Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.
        BMJ. 2007; 335: 806
        • Robles SC
        • Marrett LD
        • Clarke EA
        • Risch HA.
        An application of capture-recapture methods to the estimation of completeness of cancer registration.
        J Clin Epidemiol. 1988; 41: 495
        • Cornford P
        • Bellmunt J
        • Bolla M
        • et al.
        EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer.
        Eur Urol. 2017; 71: 630
        • Wallis CJD
        • Satkunasivam R
        • Saskin R
        • et al.
        Population-based analysis of treatment toxicity among men with castration-resistant prostate cancer: a phase IV study.
        Urology. 2018; 113: 138
        • Pound CR
        • Partin AW
        • Eisenberger MA
        • et al.
        Natural history of progression after PSA elevation following radical prostatectomy.
        JAMA. 1999; 281: 1591
        • Krahn M
        • Bremner KE
        • Tomlinson G
        • et al.
        Androgen deprivation therapy in prostate cancer: are rising concerns leading to falling use?.
        BJU Int. 2011; 108: 1588
        • Smith MR
        • Kabbinavar F
        • Saad F
        • et al.
        Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer.
        J Clin Oncol. 2005; 23: 2918
        • Stuart EA
        • Bradshaw CP
        • Leaf PJ.
        Assessing the generalizability of randomized trial results to target populations.
        Prev Sci. 2015; 16: 475
        • Nordon C
        • Karcher H
        • Groenwold RH
        • et al.
        The "Efficacy-Effectiveness Gap": historical background and current conceptualization.
        Value Health. 2016; 19: 75
        • Lokeshwar SD
        • Klaassen Z
        • Saad F.
        Treatment and trials in non-metastatic castration-resistant prostate cancer.
        Nat Rev Urol. 2021; 18: 433
        • Kirby M
        • Hirst C
        • Crawford ED.
        Characterising the castration-resistant prostate cancer population: a systematic review.
        Int J Clin Pract. 2011; 65: 1180
        • Freedland SJ
        • Pilon D
        • Bhak RH
        • et al.
        Predictors of survival, healthcare resource utilization, and healthcare costs in veterans with non-metastatic castration-resistant prostate cancer.
        Urol Oncol. 2020; 38: e13-930.e21
        • Lowrance WT
        • Murad MH
        • Oh WK
        • et al.
        Castration-resistant prostate cancer: AUA guideline amendment 2018.
        J Urol. 2018; 200: 1264
        • Howard LE
        • Moreira DM
        • De Hoedt A
        • et al.
        Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer.
        BJU Int. 2017; 120: E80
        • Whitney CA
        • Howard LE
        • Freedland SJ
        • et al.
        Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer.
        Prostate Cancer Prostatic Dis. 2019; 22: 252